Stay updated on CUE-101 Pre-Surgery or Chemoradiation in HPV16+ OPSCC Clinical Trial
Sign up to get notified when there's something new on the CUE-101 Pre-Surgery or Chemoradiation in HPV16+ OPSCC Clinical Trial page.

Latest updates to the CUE-101 Pre-Surgery or Chemoradiation in HPV16+ OPSCC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedA new revision entry, v3.6.6, was added to the record history, and the previous revision entry, v3.6.5, was removed, indicating an update to the study record's public revision history.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedThe revision history now includes a new entry for v3.6.5, replacing the previous v3.6.4 entry. This reflects an update to the page's revision metadata.SummaryDifference0.1%

- Check55 days agoChange DetectedThe study history adds Contacts/Locations and Study Status sections to the record, updating how to reach the study team and showing the current recruitment status; a new revision (v3.6.4) was released.SummaryDifference0.5%

- Check77 days agoChange DetectedThe study history gained a new revision entry (v3.6.3), replacing the previous v3.6.2, signaling an administrative update to the page's version history.SummaryDifference0.1%

- Check84 days agoChange DetectedA new revision entry v3.6.2 was added to the record history, and the previous revision v3.6.0 was removed.SummaryDifference0.1%

- Check91 days agoChange DetectedKey sections such as Contacts/Locations, Study Status, Eligibility, Outcome Measures, and Arms/Interventions appear to be removed from the study record's version history UI, affecting access to core trial information and its status history.SummaryDifference10%

Stay in the know with updates to CUE-101 Pre-Surgery or Chemoradiation in HPV16+ OPSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CUE-101 Pre-Surgery or Chemoradiation in HPV16+ OPSCC Clinical Trial page.